Nuvalent (NASDAQ:NUVL) Insider Sells $424,607.16 in Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 4,363 shares of Nuvalent stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97.32, for a total value of $424,607.16. Following the completion of the transaction, the insider directly owned 44,723 shares of the company’s stock, valued at approximately $4,352,442.36. This represents a 8.89% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Deborah Ann Miller also recently made the following trade(s):

• On Tuesday, January 6th, Deborah Ann Miller sold 2,589 shares of Nuvalent stock. The shares were sold at an average price of $97.16, for a total transaction of $251,547.24.
• On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total transaction of $2,553,100.00.
• On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The stock was sold at an average price of $103.16, for a total transaction of $2,248,888.00.
• On Monday, October 20th, Deborah Ann Miller sold 5,000 shares of Nuvalent stock. The stock was sold at an average price of $94.91, for a total transaction of $474,550.00.
• On Thursday, October 16th, Deborah Ann Miller sold 12,376 shares of Nuvalent stock. The shares were sold at an average price of $91.66, for a total transaction of $1,134,384.16.
• On Wednesday, October 15th, Deborah Ann Miller sold 15,624 shares of Nuvalent stock. The stock was sold at an average price of $89.98, for a total transaction of $1,405,847.52.

Nuvalent Trading Up 2.3%

Shares of NUVL opened at $105.05 on Friday. The business’s fifty day simple moving average is $102.85 and its two-hundred day simple moving average is $89.21. Nuvalent, Inc. has a 12 month low of $55.53 and a 12 month high of $112.88. The company has a market cap of $7.64 billion, a price-to-earnings ratio of -19.75 and a beta of 1.32.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same period in the previous year, the firm posted ($1.28) earnings per share. As a group, research analysts forecast that Nuvalent, Inc. will post -3.86 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on NUVL. JPMorgan Chase & Co. reduced their price target on shares of Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, December 19th. Stifel Nicolaus boosted their target price on shares of Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Truist Financial set a $140.00 price target on Nuvalent in a report on Monday, November 24th. Robert W. Baird lifted their price objective on Nuvalent from $112.00 to $158.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Finally, Piper Sandler increased their target price on Nuvalent from $112.00 to $128.00 and gave the company an “overweight” rating in a report on Monday, October 27th. Fifteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $138.33.

Hedge Funds Weigh In On Nuvalent

A number of institutional investors have recently bought and sold shares of NUVL. GAMMA Investing LLC grew its holdings in Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after purchasing an additional 108 shares during the period. Aster Capital Management DIFC Ltd bought a new position in shares of Nuvalent in the third quarter worth about $38,000. Eastern Bank purchased a new position in shares of Nuvalent during the 3rd quarter valued at about $52,000. Persistent Asset Partners Ltd bought a new position in shares of Nuvalent during the 2nd quarter valued at approximately $88,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Nuvalent by 9,230.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock valued at $93,000 after acquiring an additional 1,200 shares during the period. 97.26% of the stock is owned by institutional investors.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.